Patents by Inventor Philip M. Wallace

Philip M. Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Soluble CTLA4 mutant molecules and uses thereof
    Publication number: 20090317397
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 24, 2009
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Philip M. Wallace
  • Soluble CTLA4 mutant molecules
    Patent number: 7572772
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: August 11, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Philip M. Wallace
  • Oncostatin M for treating inflammation
    Patent number: 5958442
    Abstract: Oncostatin M is employed in methods to treat acute and chronic gastrointestinal inflammation, rheumatoid arthritis and multiple sclerosis.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: September 28, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventors: Philip M. Wallace, Thomas J. Brown
  • Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
    Patent number: 5814307
    Abstract: The present invention relates to methods of using oncostatin M (OM). In particular, it relates to the use of OM to stimulate interleukin 6 (IL-6) synthesis in target cells, especially human endothelial cells. The resultant IL-6, in turn, may perform a variety of functions such as cell growth regulation, leukocyte differentiation, and tumor inhibition. Furthermore, the present invention also relates to the use of OM to treat cytopenias, including anemia and thrombocytopoiesis, and to increase tolerance to irradiation and cytotoxic drugs. Therefore, the methods of the invention may have a wide range of applications, including, but not limited to, the inhibition of tumor growth, the treatment of cytopenias, and to increase the tolerance to radio- and chemotherapy. OM may be used in combination with various cytokines, including erythropoietin, colony-stimulating factors, interleukin-3 or thrombopoietin.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: September 29, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Philip M. Wallace, Thomas J. Brown
  • Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
    Patent number: 5770197
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: January 22, 1993
    Date of Patent: June 23, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Philip M. Wallace